% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hglinger:285476,
author = {Höglinger, Günter and Vandenberghe, Wim and Woitalla,
Dirk and Corvol, Jean-Christophe and Van Tricht, Hans and
Ewen, Colin and Van Den Steen, Bart and Rebollo Mesa, Irene
and Germani, Massimiliano and Garric, Elodie and Arnould,
Tasmin and Jose, Joby and Strong, Nancy and De Bruyn, Steven
and Buchanan, Tim J},
title = {{S}afety, tolerability and biomarker results of bepranemab
in participants with progressive supranuclear palsy: a
randomised, multicentre, double-blind, placebo-controlled,
phase 1b trial.},
journal = {BMJ neurology open},
volume = {8},
number = {1},
issn = {2632-6140},
address = {London},
publisher = {BMJ Publishing Group},
reportid = {DZNE-2026-00253},
pages = {e001396},
year = {2026},
abstract = {Preclinical evidence suggests targeting the mid-region of
tau as a viable therapeutic strategy in diseases such as
progressive supranuclear palsy (PSP): a rare, fatal,
neurodegenerative tauopathy with no currently approved
treatments. Bepranemab is a recombinant, humanised,
full-length immunoglobulin G4 monoclonal antibody binding to
a mid-region tau epitope. We assessed safety, tolerability
and pharmacokinetics of bepranemab in participants with
PSP.PSP003 (NCT04185415), a multicentre, double-blind,
placebo-controlled, phase 1b study, recruited participants
in hospital settings across 13 centres. Participants (aged
≥40 years) met Movement Disorder Society-PSP criteria for
possible/probable PSP, could walk ≥5 steps with minimal/no
assistance and were stable on treatment for ≥2 weeks prior
to baseline. Participants were randomised 3:1 to receive
intravenous bepranemab (90 mg/kg) or placebo every 4 weeks
for 52 weeks. Primary endpoint: incidence of
treatment-emergent adverse events (TEAEs) from baseline to
last visit.Twenty-five participants were enrolled (male:
$44\%;$ bepranemab n=18, placebo n=7). Seventeen $(94.4\%)$
in the bepranemab group reported ≥1 TEAE (five
participants; ten investigational medicinal product
(IMP)-related TEAEs), versus placebo (n=7; $100\%).$ In the
bepranemab and placebo groups, respectively, three
participants $(16.7\%)$ and one participant $(14.3\%)$
discontinued due to TEAEs. Incidence of IMP-related TEAEs
and severe TEAEs was similar between groups; no deaths were
reported. Reduction $(80.41\%)$ in mean free tau
cerebrospinal fluid levels was observed in the bepranemab
group.Multiple doses of bepranemab 90 mg/kg were well
tolerated with an acceptable safety profile in participants
with PSP. High target occupancy was observed.},
keywords = {ALZHEIMER'S DISEASE (Other) / CLINICAL NEUROLOGY (Other) /
RANDOMISED TRIALS (Other) / SUPRANUCLEAR PALSY (Other)},
cin = {Clinical Research (Munich)},
ddc = {610},
cid = {I:(DE-2719)1111015},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41789119},
pmc = {pmc:PMC12958890},
doi = {10.1136/bmjno-2025-001396},
url = {https://pub.dzne.de/record/285476},
}